Stay updated with breaking news from Thomas Chalberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Proceeds will be used to advance clinical program of GNSC-001, company's lead candidate in osteoarthritis (OA) Brian Kotzin, M.D., and Jackson Streeter, M.D.,...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
BERKELEY, CA / ACCESSWIRE / January 5, 2022 / Chameleon Biosciences Inc., a company developing the EVADERTM platform to produce next-generation gene therapies that are more potent and less immunogenic
Share this article PALO ALTO, Calif., May 5, 2021 /PRNewswire/ -- Â Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA). GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involve...